Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess the relative bioavailability of two test tablet formulations of ABT-450 as compared to the ABT-450 hard gelatin capsule formulation as a reference.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Abbott
• Treatments: Ritonavir

Criteria

Inclusion Criteria

• Overall healthy subjects

• Non-childbearing potential females included

Exclusion Criteria

• Positive test for HAV IgM, HBsAg, anti-HCV Ab or anti-HIV Ab

• Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder

• Use of tobacco or nicotine-containing products with the 6-month period prior to study drug administration

• Abnormal screening laboratory results that are considered clinically significant by the investigator

• Pregnant or breastfeeding female; requirement for any OTC and/or prescription medication, vitamins and/or herbal supplements on a regular basis

• Previous exposure to ABT-450